On 11 January 2019, orphan designation (EU/3/18/2130) was granted by the European Commission to Arena Pharmaceuticals Limited, Ireland, for ralinepag for the treatment of pulmonary arterial hypertension.
The sponsorship was transferred to Unither Therapeutik GmbH, Germany in April 2019.
|Disease / condition||
Treatment of pulmonary arterial hypertension
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
Unither Therapeutik GmbH
Tel. +49 6105 27137
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.